Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy

Internal Medicine

Volumn 46, Issue 7, 2007, Pages 359-362

  Honda, Miwako ^a   Yogi, Akira ^a   Ishizuka, Naoki ^a   Genka, Ikumi ^a   Gatanaga, Hiroyuki ^a   Teruya, Katsuji ^a   Tachikawa, Natsuo ^a   Kikuchi, Yoshimi ^a   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Antiretroviral treatment; HIV; Lipoatrophy; Recombinant human growth hormone

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN GROWTH HORMONE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FACE MUSCLE; FEMALE; FOLLOW UP; HAND PARESTHESIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPOATROPHY; LONG TERM CARE; MALE; MASTALGIA; MYALGIA; OPEN STUDY; PILOT STUDY; SKINFOLD THICKNESS; TREATMENT DURATION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTHETICS; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBABILITY; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 34247124454     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6122     Document Type: Article

References (12)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58, 1998.
2. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 292: 210-218, 2004.
3. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistributionsyndrome (lipodystrophy) in patients with HIV. AIDS 13: 2099-2103, 1999.
4. Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87: 942-945, 2002.
5. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 35: 239-252, 2004(erratum in: J Acquir Immune Defic Syndr 35: 381, 2006).
6. Moyle GJ, Daar ES, Gertner JM, et al. Growth hormone improves lean body mass, physical performance, and quality of life subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 35: 367-375, 2004.
7. Nicholas PK, Kirksey KM, Corless IB, Kemppainen J. Lipodystrophy and quality of life in HIV: symptom management issues. Appl Nurs Res 18: 55-58, 2005.
8. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 28: 979-986, 2002.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 29: S43-S48, 2006.
10. Padilla S, Gallego JA, Masia M, Gutierrez F. Single-slice computed tomography and anthriopometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients. Clin Infect Dis 39: 1848-1851, 2004.
11. Lo JC, Mulligan K, Noor MA, et al. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clinical Infectious Diseases 39: 732-735, 2004.
12. Andersen O, Haugaard SB, Flyvbjerg A, et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur J Clin Invest 34: 561-568, 2004.